NCT01346319View on ClinicalTrials.gov

Study of the Safety, Tolerability and Pharmacokinetics of Testosterone Undecanoate in Hypogonadal Males.

PHASE1CompletedINTERVENTIONAL
0
Timeline

Start Date

April 30, 2011

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Hypogonadal Males
Interventions
DRUG

ABT-SLV361

For dose groups 1, 2 and 3 medication is taken 1 time per day the first day followed by 2 times per day for 14 days. For dose groups 4 and 5, medication is taken 1 time per day for the first day followed by 2 times per day for 28 days.

DRUG

placebo

For dose groups 1, 2 and 3 medication is taken 1 time per day the first day followed by 2 times per day for 14 days. For dose groups 4 and 5, medication is taken 1 time per day for the first day followed by 2 times per day for 28 days.

Trial Locations (1)

33901-0000

Site Reference ID/Investigator# 51964, Fort Myers

Sponsors

Lead Sponsor

Abbott
All Listed Sponsors
lead

Abbott

INDUSTRY

NCT01346319 - Study of the Safety, Tolerability and Pharmacokinetics of Testosterone Undecanoate in Hypogonadal Males. | Biotech Hunter | Biotech Hunter